(Yicai Global) Jan. 29 -- Two Chinese and German firms will collaborate to establish a Chimeric Antigen Receptor, also known as CAR, T cell preparation factory in China to provide services to cancer patients through immunocellular therapy.

China's PersonGen-Anke Cellular Therapeutics Co. signed a Memorandum of Understanding with Germany's Miltenyi Biotec to set up the project in Hefei, East China's Anhui province, said a statement issued by the parent company Anhui Anke Biotechnology (Group) Co. [SHE:300009]. However, it did not provide any financial details of the deal. The statement also fell short of clarifying whether the cell preparation factory will be a joint venture or PersonGen-Anke will just buy relevant technologies from the German company.

Miltenyi will provide the Chinese firm with its automated manufacturing solutions and the quality control of CAR T cells to boost the latter's research and development and production and the quality control of CAR T cell technology to help improve its competitiveness, the statement said.

Miltenyi is a leading company on cell preparation and relevant technologies and will provide strong support to PersonGen-Anke's CAR T therapy, it added. Both firms will also conduct in-depth cooperation on CAR T therapy and strengthen supply side of their bilateral collaboration. They will jointly develop custom reagents and carry out R & D projects in immunotherapy.